Return to Listing

5 result(s) for Myelodysplastic Syndrome

PI Name Protocol # Title
Emma Scott STUDY00015214 A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Kim-Hien Dao STUDY00015363 WEAR in Oregon: Defining risks of blood cancer development in a cohort of older women with clonal hematopoiesis and TET2 mutations. (Women Engaged in Advancing health Research in Oregon is a prospective epidemiology study)
Laura Newell STUDY00015619 A phase 1/2 study of Vadastuximab Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate -2 or high-risk Myelodysplastic Syndrome (MDS).
Kim-Hien Dao STUDY00015977 [NCI CIRB] The National Myelodysplastic Syndromes (MDS) Study
Richard Maziarz STUDY00016189 A Phase 1 Non-Randomized/Phase 2 Randomized Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Hematologic Malignancies
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080